Published in Proc Natl Acad Sci U S A on January 30, 2012
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol (2012) 2.07
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol (2012) 1.90
A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One (2012) 1.81
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J Exp Med (2015) 1.50
Pandemic H1N1 Influenza Infection and Vaccination in Humans Induces Cross-Protective Antibodies that Target the Hemagglutinin Stem. Front Immunol (2012) 1.50
Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med (2013) 1.49
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A (2014) 1.49
H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol (2013) 1.48
Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med (2013) 1.47
Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting. Science (2016) 1.46
Structural insights into key sites of vulnerability on HIV-1 Env and influenza HA. Immunol Rev (2012) 1.44
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis (2012) 1.41
Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. J Virol (2012) 1.40
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza season. Proc Natl Acad Sci U S A (2014) 1.37
Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog (2013) 1.30
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol (2014) 1.26
Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J Vis Exp (2013) 1.23
Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol (2014) 1.20
Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol (2014) 1.15
H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol (2013) 1.14
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol (2013) 1.13
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol (2014) 1.13
Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol (2013) 1.12
Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog (2014) 1.11
An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol (2014) 1.06
Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One (2013) 1.06
Immune history profoundly affects broadly protective B cell responses to influenza. Sci Transl Med (2015) 1.06
Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One (2012) 1.05
Global Spatio-temporal Patterns of Influenza in the Post-pandemic Era. Sci Rep (2015) 1.01
Animal models for influenza viruses: implications for universal vaccine development. Pathogens (2014) 0.99
Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy. Cell (2015) 0.99
High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine. J Infect Dis (2015) 0.98
Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine (2015) 0.96
NS1-truncated live attenuated virus vaccine provides robust protection to aged mice from viral challenge. J Virol (2012) 0.95
Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. MBio (2016) 0.94
Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS One (2013) 0.93
Simplified large-scale Sanger genome sequencing for influenza A/H3N2 virus. PLoS One (2013) 0.92
Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J Virol (2015) 0.92
Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J Immunol Res (2014) 0.91
Epidemiology of the influenza A virus H5N1 subtype and memory of immunity to the H2N2 subtype. MBio (2012) 0.90
Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. J Virol (2015) 0.90
Intranasal adenovirus-vectored vaccine for induction of long-lasting humoral immunity-mediated broad protection against influenza in mice. J Virol (2014) 0.89
Universal influenza vaccines, a dream to be realized soon. Viruses (2014) 0.89
Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio (2016) 0.88
Pseudotype-based neutralization assays for influenza: a systematic analysis. Front Immunol (2015) 0.88
The effect of age and recent influenza vaccination history on the immunogenicity and efficacy of 2009-10 seasonal trivalent inactivated influenza vaccination in children. PLoS One (2013) 0.88
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc Natl Acad Sci U S A (2016) 0.88
Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol (2015) 0.86
Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques. J Virol (2014) 0.85
Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol (2016) 0.85
Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing. Br J Clin Pharmacol (2013) 0.85
Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains. J Virol (2015) 0.84
Influenza virus infection in guinea pigs raised as livestock, Ecuador. Emerg Infect Dis (2012) 0.84
Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. J Transl Med (2013) 0.84
Novel universal influenza virus vaccine approaches. Curr Opin Virol (2016) 0.82
Humoral antibody response after receipt of inactivated seasonal influenza vaccinations one year apart in children. Pediatr Infect Dis J (2012) 0.82
Options and obstacles for designing a universal influenza vaccine. Viruses (2014) 0.82
Protective immunity based on the conserved hemagglutinin stalk domain and its prospects for universal influenza vaccine development. Biomed Res Int (2014) 0.82
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio (2016) 0.81
Comparative serological assays for the study of h5 and h7 avian influenza viruses. Influenza Res Treat (2013) 0.80
Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front Immunol (2016) 0.79
Prospects of HA-based universal influenza vaccine. Biomed Res Int (2015) 0.79
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins. J Virol (2016) 0.79
Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies. J Virol (2015) 0.78
Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. J Virol (2013) 0.78
Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol (2016) 0.77
Partial protection against 2009 pandemic influenza A (H1N1) of seasonal influenza vaccination and related regional factors: Updated systematic review and meta-analyses. Hum Vaccin Immunother (2015) 0.77
Punctuated evolution of influenza virus neuraminidase (A/H1N1) under opposing migration and vaccination pressures. Biomed Res Int (2014) 0.77
Single dose vaccination of the ASO3-adjuvanted A(H1N1)pdm09 monovalent vaccine in health care workers elicits homologous and cross-reactive cellular and humoral responses to H1N1 strains. Hum Vaccin Immunother (2015) 0.76
Transient humoral protection against H5N1 challenge after seasonal influenza vaccination of humans. PLoS One (2014) 0.76
Baculovirus Displaying Hemagglutinin Elicits Broad Cross-Protection against Influenza in Mice. PLoS One (2016) 0.76
Chimeric influenza haemagglutinins: Generation and use in pseudotype neutralization assays. MethodsX (2016) 0.75
Passive broad-spectrum influenza immunoprophylaxis. Influenza Res Treat (2014) 0.75
Association between Hemagglutinin Stem-Reactive Antibodies and Influenza A/H1N1 Virus Infection during the 2009 Pandemic. J Virol (2016) 0.75
Post-pandemic seroprevalence of human influenza viruses in domestic cats. J Vet Sci (2016) 0.75
Does exposure to poultry and wild fowl confer immunity to H5N1? Chin Med J (Engl) (2014) 0.75
Vaccine efficacy of an inactivated, chimeric HA H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy. J Virol (2017) 0.75
Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination. J Infect Dis (2016) 0.75
INFLUENZA SURVEILLANCE IN RUSSIA BASED ON EPIDEMIOLOGICAL AND LABORATORY DATA FOR THE PERIOD FROM 2005 TO 2012. Am J Infect Dis (2015) 0.75
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins. Nat Immunol (2017) 0.75
A modified vaccinia Ankara vaccine vector expressing a mosaic H5 hemagglutinin reduces viral shedding in rhesus macaques. PLoS One (2017) 0.75
Synthetic TLR4 and TLR7 ligands work additively via MyD88 to induce protective antiviral immunity in mice. J Virol (2017) 0.75
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med (2002) 11.85
Rescue of influenza A virus from recombinant DNA. J Virol (1999) 11.54
Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med (1953) 11.41
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science (2011) 7.86
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol (1993) 6.26
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong-68 virus. Proc Natl Acad Sci U S A (1969) 4.84
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis (2006) 3.66
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Original antigenic sin responses to influenza viruses. J Immunol (2009) 2.76
Why do influenza virus subtypes die out? A hypothesis. MBio (2011) 1.92
Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol (2010) 1.74
Protection against the mouse-adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J Virol (1994) 1.72
Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol (2008) 1.64
The emergence of pandemic influenza viruses. Protein Cell (2010) 1.52
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog (2010) 1.46
An enzymatic virus-like particle assay for sensitive detection of virus entry. J Virol Methods (2009) 1.42
Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies. Arch Virol (2003) 1.24
Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proc Natl Acad Sci U S A (2011) 1.17
Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. Vaccine (2011) 1.09
Biochemistry. Catching a moving target. Science (2011) 1.02
Natural influenza A virus infection of mice elicits strong antibody response to HA2 glycopolypeptide. Acta Virol (2002) 0.86
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med (2011) 13.18
Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog (2007) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog (2009) 6.09
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Human host factors required for influenza virus replication. Nature (2010) 5.28
Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A (2003) 5.21
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 4.99
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol (2006) 4.74
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A (2007) 3.98
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
High temperature (30 degrees C) blocks aerosol but not contact transmission of influenza virus. J Virol (2008) 3.77
Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science (2012) 3.74
Gain-of-function experiments on H7N9. Science (2013) 3.67
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2009) 3.30
Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A (2012) 3.27
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science (2007) 3.16
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol (2007) 3.04
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol (2006) 2.78
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol (2007) 2.62
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med (2010) 2.59
The biology of influenza viruses. Vaccine (2008) 2.58
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44